Financial Comparison: TriplePoint Venture Growth BDC (NYSE:TPVG) versus Site Centers (NYSE:SITC)

Site Centers (NYSE:SITC) and TriplePoint Venture Growth BDC (NYSE:TPVG) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Risk and Volatility

Site Centers has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, TriplePoint Venture Growth BDC has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.

Insider and Institutional Ownership

88.7% of Site Centers shares are owned by institutional investors. Comparatively, 12.8% of TriplePoint Venture Growth BDC shares are owned by institutional investors. 0.2% of Site Centers shares are owned by company insiders. Comparatively, 1.5% of TriplePoint Venture Growth BDC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Site Centers and TriplePoint Venture Growth BDC”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Site Centers	$113.49 million	1.59	$177.86 million	$2.41	1.43
TriplePoint Venture Growth BDC	$90.93 million	2.20	$49.21 million	$0.99	4.95

Site Centers has higher revenue and earnings than TriplePoint Venture Growth BDC. Site Centers is trading at a lower price-to-earnings ratio than TriplePoint Venture Growth BDC, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Site Centers and TriplePoint Venture Growth BDC, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Site Centers	2	1	0	0	1.33
TriplePoint Venture Growth BDC	1	5	0	0	1.83

Site Centers presently has a consensus price target of $3.50, indicating a potential upside of 1.89%. TriplePoint Venture Growth BDC has a consensus price target of $5.25, indicating a potential upside of 7.03%. Given TriplePoint Venture Growth BDC’s stronger consensus rating and higher probable upside, analysts plainly believe TriplePoint Venture Growth BDC is more favorable than Site Centers.

Profitability

This table compares Site Centers and TriplePoint Venture Growth BDC’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Site Centers	219.18%	40.56%	27.81%
TriplePoint Venture Growth BDC	44.58%	10.68%	4.58%

Summary

Site Centers beats TriplePoint Venture Growth BDC on 7 of the 13 factors compared between the two stocks.

About Site Centers

SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.

About TriplePoint Venture Growth BDC

TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company’s total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.